A Study About the Use of Omalizumab in the Treatment of Food Allergy and Anaphylaxis

Completed

Conditions studied: Food Hypersensitivity, Anaphylaxis

In brief

This was a retrospective, multi-center observational study conducted across four allergy departments in Europe (Berlin, Leipzig, Barcelona, and Basel). The study included patients with immunoglobulin E (IgE)-mediated food allergy who were treated with omalizumab, either as monotherapy or in combination with oral immunotherapy (OIT) between 2002-2022.

Key facts

Study ID

NCT07027163

Run by

Novartis Pharmaceuticals

People needed

62

Starts

2023-06-01

Expected to finish

2023-09-01

Last updated by the study team

2025-06-18

Who can join

Age: 6 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• A confirmed history of food allergy, either with or without prior anaphylaxis.
• Treated with omalizumab, either as monotherapy or in combination with OIT.

You may not qualify if…

• None identified.

Where it is running

• Novartis — East Hanover, New Jersey, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.